Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4

KM Beeh, O Kornmann, R Buhl, SV Culpitt… - Chest, 2003 - Elsevier
Study objectives: Neutrophilic inflammation is a major feature of COPD. Several factors in
bronchial secretions have been identified as chemoattractants for neutrophils. The present …

[HTML][HTML] Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme

…, JM Hohlfeld, AM Kirsten, O Kornmann… - … England Journal of …, 2015 - Mass Medical Soc
Background The most prevalent phenotype of asthma is characterized by eosinophil-dominated
inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of …

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

O Kornmann, R Dahl, S Centanni… - European respiratory …, 2011 - Eur Respiratory Soc
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2 -agonist bronchodilator
recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). …

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma

ED Bateman, O Kornmann, P Schmidt… - Journal of Allergy and …, 2011 - Elsevier
BACKGROUND: The efficacy and safety of inhaled long-acting β 2 -adrenergic agonists in
asthmatic patients with the B16-Arg/Arg genotype has been questioned, and the use of …

[HTML][HTML] Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in …

C Gessner, O Kornmann, J Maspero, R van Zyl-Smit… - Respiratory …, 2020 - Elsevier
Background The efficacy and safety of once-daily (od) fixed-dose combination of indacaterol
(IND), glycopyrronium (GLY) and mometasone furoate (MF) via BreezhalerŽ versus …

[HTML][HTML] Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

WC Moore, O Kornmann, M Humbert… - European …, 2022 - Eur Respiratory Soc
Background The long-term efficacy and safety of mepolizumab for treatment of severe
eosinophilic asthma are well established. Here, we examine the clinical impact of stopping …

[HTML][HTML] Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

IJ Pouliquen, O Kornmann, SV Barton… - … journal of clinical …, 2015 - ncbi.nlm.nih.gov
Objective: Mepolizumab is a humanized IgG1 monoclonal antibody that blocks human IL-5
from binding to the IL-5 receptor, which is mainly expressed on eosinophils. Eosinophils are …

[HTML][HTML] Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

…, BE Davis, S Korn, O Kornmann… - European …, 2023 - Eur Respiratory Soc
Background Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic
inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent …

[HTML][HTML] A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

…, P Chanez, A Chuchalin, A D'Urzo, O Kornmann… - Respiratory …, 2008 - Elsevier
This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol,
a novel once-daily inhaled β 2 -agonist, in subjects clinically diagnosed with COPD. …

Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD

KM Beeh, J Beier, O Kornmann, A Mander, R Buhl - Chest, 2003 - Elsevier
Study objectives Neutrophilic inflammation is a major feature of COPD. Induced sputum is
increasingly used to monitor inflammatory airway diseases. Although short-term repeatability …